Alveus Therapeutics Funding: $197M Raised, Series A (2026)
Alveus Therapeutics is a Biotech company based in Philadelphia, Pennsylvania. It has raised $197M in total funding. Latest round: Series A.
Alveus Therapeutics funding overview
Alveus Therapeutics is a Biotech company based in Philadelphia, Pennsylvania. Alveus Therapeutics has raised $197M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in February 2026. The round record for Alveus Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital and 2 others. 8 distinct backers are named across the disclosed rounds.
Alveus Therapeutics at a glance
Total raised
$197M
Latest round
Series A
Latest round date
February 2026
Industry
Biotech
Headquarters
Philadelphia, Pennsylvania
Notable investors
New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital, Jeito Capital, Novo Holdings
Frequently asked about Alveus Therapeutics funding
How much has Alveus Therapeutics raised?
Alveus Therapeutics has raised $197M in total disclosed funding across the rounds on record.
Who has invested in Alveus Therapeutics?
New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital are named among the investors backing Alveus Therapeutics.
What was the latest Alveus Therapeutics funding round?
The most recent disclosed round is a Series A, announced in February 2026.
Where is Alveus Therapeutics based?
Alveus Therapeutics is based in Philadelphia, Pennsylvania.
What sector does Alveus Therapeutics operate in?
Alveus Therapeutics is tracked under Biotech from Philadelphia, Pennsylvania, with $197M in disclosed funding.
When did Alveus Therapeutics last raise?
The last disclosed Alveus Therapeutics round closed in February 2026 at Series A.
Totals shown for Alveus Therapeutics aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Philadelphia and the investors behind them below.
